These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29468647)

  • 1. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
    Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
    Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
    Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
    Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
    Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
    Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.
    Tsirigotis P; Danylesko I; Gkirkas K; Shem-Tov N; Yerushalmi R; Stamouli M; Avigdor A; Spyridonidis A; Gauthier J; Goldstein G; Apostolidis J; Mohty M; Shimoni A; Nagler A
    Bone Marrow Transplant; 2016 Oct; 51(10):1313-1317. PubMed ID: 27183095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
    Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
    Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 10. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM).
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):15-7. PubMed ID: 24870877
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
    Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
    Tsirigotis P; Vassilakopoulos T; Batsis I; Bousiou Z; Gkirkas K; Sakellari I; Kaloyannidis P; Roussou P; Pangalis GA; Moschogiannis M; Vassilopoulos G; Repousis P; Megalakaki A; Michalis E; Kalpadakis C; Papadaki HA; Kotsianidis I; Hatzimichael E; Spyridonidis A; Anargyrou K; Poulakidas E; Giannoullia P; Apostolidis I; Stamouli M; Konstantopoulos K; Pappa V; Panayiotidis P; Harhalakis N; Anagnostopoulos A; Angelopoulou M
    Hematol Oncol; 2018 Oct; 36(4):645-650. PubMed ID: 29882363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
    Deau B; Amorim S; Perrot A; Quittet P; Cornillon J; Chaoui D; Marolleau JP; Oberic L; Le Du K; Fornecker LM; Tournilhac O; Veillard AS; Chaillol I; Robin M; Tamburini J; Brice P
    Br J Haematol; 2018 May; 181(3):341-349. PubMed ID: 29611187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
    Walewski J; Hellmann A; Siritanaratkul N; Ozsan GH; Ozcan M; Chuncharunee S; Goh AS; Jurczak W; Koren J; Paszkiewicz-Kozik E; Wang B; Singh S; Huebner D; Engert A; von Tresckow B
    Br J Haematol; 2018 Nov; 183(3):400-410. PubMed ID: 30168134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
    Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
    Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
    Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
    Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
    Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
    Anderlini P; Saliba RM; Ledesma C; Plair T; Alousi AM; Hosing CM; Khouri IF; Nieto Y; Popat UR; Shpall EJ; Fanale MA; Hagemeister FB; Oki Y; Neelapu S; Romaguera JE; Younes A; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1333-1337. PubMed ID: 27064056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
    Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.